Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325305 | 0.90 | HTT (0.49) | NPC1RAB9AALDH1A1TSHR | |
| SCHEMBL13325140 | 0.90 | ADORA3 (0.51) | PTGDR2RAB9AALDH1A1TSHR | |
| SCHEMBL13325204 | 0.89 | ALDH1A1 (0.55) | NPC1ALDH1A1 | |
| SCHEMBL13325205 | 0.89 | ELANE (0.44) | ALDH1A1TSHRKMT2A | |
| SCHEMBL4576362 | 0.89 | CYP19A1 (0.45) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL13325256 | 0.88 | ADORA3 (0.50) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL13325206 | 0.88 | MAPT (0.44) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL13325279 | 0.88 | ALDH1A1 (0.48) | ALDH1A1TSHRKMT2A | |
| SCHEMBL13325250 | 0.88 | PDE6D (0.49) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL4576601 | 0.88 | ADORA3 (0.49) | NPC1RAB9AALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | GABRB1, GABBR2, GABBR1 | PTGDR2 121/4885CNR2 157/4885NPC1 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.